

01 Oct 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-collaborative-framework-for-resolution-of-disputes-with-the-us-food-and-drug-administration-302573077.html

25 Sep 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-the-publication-in-plos-one-of-an-article-titled-melatonin-agonist-tasimelteon-hetlioz-improves-sleep-in-patients-with-primary-insomnia-a-multicenter-randomized-double-blind-placebo-controll-302567056.html

21 Aug 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/vanda-seeks-fda-commissioner-review-of-outgoing-cder-directors-decision-to-uphold-approval-of-two-generic-versions-of-hetlioz-302536237.html

18 Aug 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/in-a-major-win-for-vanda-a-federal-appeals-court-overturns-fdas-order-denying-approval-of-hetlioz-for-the-treatment-of-jet-lag-disorder-302531842.html

14 Apr 2025
// FIERCE PHARMA
https://www.fiercepharma.com/marketing/after-hetliozs-rejection-jet-lag-vanda-sues-fda-right-promote-label-usage

17 May 2024
// FDA
https://www.pharmacompass.com/pdf/news/fda-confirms-para-iv-patent-for-tasimelteon-hetlioz-lq-oral-suspension-24597.pdf